Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study

NCT01194830 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01194830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01194830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2010
Completion date
October 31, 2011
Enrollment
234 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2